Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

Ji-Wen Wu · SciRah

Researcher profile · Semantic Scholar

Ji-Wen Wu

Share profile

Ji-Wen Wu — researcher profile on SciRah

h-index: 7
Works: 23
Citations: 232

Most-cited papers

Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women With Clinically Aggressive Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer
Yen-Shen Lu, Eznal Izwadi Bin Mohd Mahidin, H. Azim, Y. Eralp +18 more
2024Journal of Clinical Oncology77 citations Open access
Semantic Scholar
Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population
M. de Laurentiis, S. Borštnar, M. Campone, E. Warner +14 more
2021Breast Cancer Research and Treatment38 citations Open access
Semantic Scholar
Abstract GS1-10: Primary results from the randomized Phase II RIGHT Choice trial of premenopausal patients with aggressive HR+/HER2− advanced breast cancer treated with ribociclib + endocrine therapy vs physician’s choice combination chemotherapy
Yen-Shen Lu, Eznal Izwadi Bin Mohd Mahidin, H. Azim, Y. Eralp +9 more
2023Cancer Research37 citations
Semantic Scholar
Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [177Lu]Lu-PSMA-617 in the Phase 3 VISION Trial
A. Armstrong, O. Sartor, J. de Bono, Kim N. Chi +10 more
2024European Urology26 citations Open access
Semantic Scholar
Ribociclib plus letrozole in subgroups of special clinical interest with hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: Subgroup analysis of the phase IIIb CompLEEment-1 trial
P. Cottu, A. Ring, H. Abdel-Razeq, P. Marchetti +6 more
2022Breast20 citations Open access
Semantic Scholar
Ribociclib plus letrozole in male patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: subgroup analysis of the phase IIIb CompLEEment-1 trial
M. Campone, M. de Laurentiis, C. Zamagni, I. Kudryavcev +7 more
2022Breast Cancer Research and Treatment17 citations
Semantic Scholar
Outcomes with first-line (1L) ribociclib (RIB) + endocrine therapy (ET) vs physician’s choice combination chemotherapy (combo CT) by age in pre/perimenopausal patients (pts) with aggressive HR+/HER2− advanced breast cancer (ABC): A subgroup analysis of the RIGHT Choice trial.
N. E. El Saghir, Y. Yap, Y. Eralp, S. Im +12 more
2023Journal of Clinical Oncology8 citations
Semantic Scholar
Ribociclib (RIBO) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) with no prior endocrine therapy (ET) for ABC: Preliminary results from the phase 3b CompLEEment-1 trial.
M. de Laurentiis, P. Neven, G. Jerusalem, T. Bachelot +13 more
20184 citations
Semantic Scholar
Updated results from the phase IIIb complement-1 study of ribociclib (RIB) plus letrozole (LET) in the treatment of HR+, HER2-advanced breast cancer (ABC).
M. de Laurentiis, S. Borštnar, M. Campone, E. Warner +14 more
20202 citations
Semantic Scholar
Interim results from the full population of the phase 3b CompLEEment-1 study of ribociclib (RIBO) plus letrozole (LET) in the treatment of HR+/HER2– advanced breast cancer (ABC).
M. de Laurentiis, S. Borštnar, M. Campone, E. Warner +14 more
2019Journal of Clinical Oncology2 citations
Semantic Scholar
Abstract P1-18-11: Analysis of first-line (1L) patients (pts) with de novo disease vs late relapse and all pts with vs without prior chemotherapy (CT) in the MONALEESA-3 (ML-3) trial
M. de Laurentiis, M. Lambertini, S. Chia, H. Rugo +9 more
2022Cancer Research1 citations
Semantic Scholar
Abstract P5-13-25: PIK3CA registry: A noninterventional, descriptive, retrospective cohort study of PIK3CA mutations in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC)
P. Rajadurai, T. Semiglazova, A. Hegmane, F. El Karak +10 more
2022Cancer Research1 citations
Semantic Scholar
A multi-centre, stratified, open, randomized, comparator-controlled, parallel group phase II trial comparing adjuvant treatment with 177Lu-DOTATATE to standard of care in patients after resection of neuroendocrine liver metastases (NELMAS).
A. Frilling, R. P. Baum, K. Veselkov, Elena Ferrer Martinez Del Peral +9 more
2025Journal of Clinical Oncology0 citations
Semantic Scholar
Corrigendum to "Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [177Lu]Lu-PSMA-617 in the Phase 3 VISION Trial" [Eur. Urol. 86 (2024) 552-562].
A. Armstrong, O. Sartor, J. de Bono, Kim N. Chi +10 more
2025European Urology0 citations Open access
Semantic Scholar
Abstract PS10-10: Ribociclib + letrozole in premenopausal patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC): Subgroup analysis of the phase IIIb CompLEEment-1 trial
H. A. Razeq, P. Cottu, A. Ring, M. de Laurentiis +7 more
2021Poster Session Abstracts0 citations
Semantic Scholar
Correction to: Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population
M. de Laurentiis, S. Borštnar, M. Campone, E. Warner +14 more
2021Breast Cancer Research and Treatment0 citations Open access
Semantic Scholar
Abstract PS14-03: Ribociclib + letrozole in male patients with hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2−) advanced breast cancer (ABC): Subgroup analysis of the phase IIIb CompLEEment-1 trial
M. Campone, M. de Laurentiis, C. Zamagni, I. Kudryavcev +8 more
2021Poster Session Abstracts0 citations
Semantic Scholar
Abstract PS14-07: Ribociclib + letrozole in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2−) advanced breast cancer (ABC) and central nervous system metastases: Subgroup analysis of the phase IIIb CompLEEment-1 trial
P. Cottu, M. de Laurentiis, P. Marchetti, L. Coltelli +9 more
2021Poster Session Abstracts0 citations
Semantic Scholar
Abstract PS10-05: Ribociclib + letrozole in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2−) advanced breast cancer (ABC): Expanded safety analysis of the phase IIIb CompLEEment-1 trial
Janice M. Lu, P. Cottu, Miguel Martín, C. Zamagni +10 more
2021Poster Session Abstracts0 citations
Semantic Scholar
Abstract P1-19-21: Ribociclib + letrozole in patients with HR+, HER2− advanced breast cancer: Safety analysis of the phase 3b CompLEEment-1 trial
Janice M. Lu, P. Cottu, Miguel Martín, C. Zamagni +4 more
20200 citations
Semantic Scholar
RIBOCICLIB (RIB) + LETROZOLE (LET) IN OLDER PATIENTS (PTS) WITH HORMONE RECEPTOR-POSITIVE (HR+), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR-2–NEGATIVE (HER2–) ADVANCED BREAST CANCER (ABC): SUBGROUP RESULTS FROM THE PHASE 3B COMPLEEMENT-1 TRIAL
M. de Laurentiis, M. Campone, E. Conejo, M. Tanner +9 more
2019Breast0 citations
Semantic Scholar
A PLAIN-LANGUAGE SUMMARY OF THE COMPLEEMENT-1 STUDY: RIBOCICLIB AND LETROZOLE AS FIRST LINE THERAPY IN A STUDY OF 3,246 PEOPLE WITH ADVANCED BREAST CANCER
E. Warner, M. de Laurentiis, Miguel Martín, P. Cottu +7 more
2019Breast0 citations
Semantic Scholar
RIBOCICLIB (RIB) + LETROZOLE (LET) IN PATIENTS WITH HORMONE RECEPTOR-POSITIVE (HR+), HUMAN EPIDERMAL RECEPTOR-2–NEGATIVE (HER2–) ADVANCED BREAST CANCER (ABC) BY DOSE INTENSITY: PRELIMINARY SUBGROUP RESULTS FROM THE PHASE 3B COMPLEEMENT-1 TRIAL
Fadi Farhat, Miguel Martín, M. Campone, T. Bachelot +9 more
2019Breast0 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

Miguel Martín×13
Invite
Miguel Martín — researcher profile on SciRah
K. Zhou×13
Invite
K. Zhou — researcher profile on SciRah
M. de Laurentiis×13
Invite
M. de Laurentiis — researcher profile on SciRah
P. Cottu×11
Invite
P. Cottu — researcher profile on SciRah

×11

Invite

C. Zamagni — researcher profile on SciRah

Invite

H. Azim — researcher profile on SciRah

Janice M. Lu×9

Invite

Janice M. Lu — researcher profile on SciRah

L. Menon-Singh×9

Invite

L. Menon-Singh — researcher profile on SciRah

Invite

M. Campone — researcher profile on SciRah

Invite

A. Ring — researcher profile on SciRah

Invite

E. Warner — researcher profile on SciRah

Invite

S. Dent — researcher profile on SciRah